Zions Bancorporation N.A. Raises Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Zions Bancorporation N.A. lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 18.7% in the fourth quarter, Holdings Channel reports. The firm owned 10,121 shares of the medical research company’s stock after buying an additional 1,594 shares during the period. Zions Bancorporation N.A.’s holdings in Charles River Laboratories International were worth $1,868,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of CRL. Charles Schwab Investment Management Inc. grew its position in shares of Charles River Laboratories International by 6.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock worth $101,483,000 after buying an additional 32,311 shares in the last quarter. Raymond James Trust N.A. bought a new position in Charles River Laboratories International during the 3rd quarter worth about $211,000. Cerity Partners LLC grew its holdings in Charles River Laboratories International by 65.9% during the 3rd quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company’s stock worth $963,000 after acquiring an additional 1,943 shares in the last quarter. Daiwa Securities Group Inc. increased its position in Charles River Laboratories International by 12.6% during the 3rd quarter. Daiwa Securities Group Inc. now owns 6,355 shares of the medical research company’s stock valued at $1,252,000 after purchasing an additional 710 shares during the period. Finally, Fisher Asset Management LLC raised its holdings in shares of Charles River Laboratories International by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 184,692 shares of the medical research company’s stock valued at $36,379,000 after purchasing an additional 1,586 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $189.77.

Charles River Laboratories International Stock Down 3.2 %

NYSE:CRL opened at $161.57 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $273.32. The company has a market cap of $8.26 billion, a PE ratio of 1,077.13, a P/E/G ratio of 4.54 and a beta of 1.45. The company’s 50 day moving average is $165.32 and its two-hundred day moving average is $183.30.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.46 earnings per share. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James C. Foster bought 6,075 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).